Table 3.
Cardiovascular biomarkers and outcomes during index type 1 MI admission between patients with systemic inflammatory disease and controls
| Individuals without systemic inflammatory disease (n = 2044) | Individuals with systemic inflammatory disease (n = 53) | P-value | |
|---|---|---|---|
| Laboratory values, median (IQR) | |||
| Total cholesterol (mg/dL) | 187 (158–218) | 185 (148–229) | 0.71 |
| Triglycerides (mg/dL) | 149 (102–223) | 164 (130–274) | 0.04 |
| HDL-C (mg/dL) | 36 (30–42) | 35.0 (28–39) | 0.072 |
| LDL-C (mg/dL) | 116 (91–142) | 110 (79–149) | 0.5 |
| Max troponin | 42.2 (10.7–152) | 14.2 (3.8–57) | 0.003 |
| Creatinine (mg/dL) | 1.0 (0.9–1.1) | 1.0 (0.9–1.2) | 0.71 |
| Discharge medications,an (%) | |||
| Aspirin | 1898 (94.7%) | 43 (87.8%) | 0.04 |
| Statin therapy | 1793 (89.4%) | 37 (75.5%) | 0.002 |
| P2Y12 inhibitor | 1640 (81.8%) | 36 (73.5%) | 0.14 |
| Beta-blocker | 1834 (91.5%) | 41 (83.7%) | 0.06 |
| ACE inhibitor/ARB | 1240 (61.8%) | 27 (55.1%) | 0.34 |
| Outcomes, n (%) | |||
| Cardiac cath | 1923 (94.1%) | 48 (90.6%) | 0.29 |
| Coronary revascularization | 1690 (82.7%) | 45 (84.9%) | 0.67 |
| CABG | 199 (9.7%) | 7 (13.2%) | 0.4 |
ARB, angiotensin receptor blocker; CABG, coronary artery bypass graft; HDL-C, high-density lipoprotein cholesterol; IQR, interquartile range; LDL, low-density lipoprotein cholesterol.
Shown are admission labs with median values with IQR except for troponin. Troponin was standardized by the assay upper limit of normal and then a maximum median value is shown.20 Lipid values reflect >85% of individuals without SID and n = 49 with SID.
a
Discharge medications reflect 2005 patient’s without SID that were discharged and 49 patients with SID that were discharged.